Compare Arista Networks Inc (ANET) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arista Networks Inc vs BIO-TECHNE Corp — how do they compare? Arista Networks Inc trades at $197.67 (market cap $241.55B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Arista Networks Inc is far larger — about 21.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Arista Networks Inc pays none. Which is the better fit depends on your goals.
| ANET | TECH | |
|---|---|---|
Market Cap | $241.55B | $11.24B |
Sector | Technology | Health |
52-Week High | $197.31 | $72.29 |
52-Week Low | $116.13 | $43.31 |
Enterprise Value | $228.21B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $188.67, down 1.9% over 24 hours, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, with revenue growing from $4.4B in 2022 to $9.0B in 2025 and a net income margin of 38.37%. Recent earnings beats and raised 2026 guidance reflect robust AI-driven demand from hyperscalers like Meta and Microsoft.
Outlook remains positive due to AI data center expansion and Ethernet market growth, but high valuation multiples (P/E 59.71) pose risks if execution falters. Analyst consensus is strongly bullish with a $252.25 price target, though insider selling and competition require monitoring for sustained gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
